Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 204

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Assessment of Plasma Total Tau Level as a Predictive Biomarker for Dementia and Related Endophenotypes

Open access
Pase, Matthew P., Beiser, Alexa S., Himali, Jayandra J., Satizabal, Claudia L., Aparicio, Hugo J., DeCarli, Charles, Chêne, Geneviève, Dufouil, Carole, Seshadri, Sudha · 2019 · JAMA Neurology

Abstract

Importance: Blood-based biomarkers have the potential to improve the identification of persons with the greatest dementia risk for inclusion in dementia prevention trials through low-cost and minimally invasive screening. Objective: To investigate the use of plasma total tau as a blood biomarker for dementia and related endophenotypes. Design, Setting, and Participants: This prospective cohort study used data from the US community-based Framingham Heart Study with replication in the Memento study, a multicenter cohort of persons with mild cognitive impairment or subjective cognitive complaints recruited from memory clinics across France. Total tau levels were measured from stored plasma samples in Framingham Heart Study participants during 2004 to 2011. Dementia follow-up occurred across a median of 6 years (interquartile range, 5-8 years) for persons 65 years and older who were dementia free at baseline. Plasma and/or cerebrospinal fluid samples were obtained from Memento study participants from April 19, 2011, to June 22, 2016. Dementia follow-up took place over a median of 4 years (interquartile range, 3-5 years). Data analysis was performed from January to November 2018. Exposures: Plasma total tau level measured using single-molecule array technology. Main Outcomes and Measures: Incidence of dementia of any cause (all dementia) and dementia due to clinical Alzheimer disease (AD dementia). Results: Among the 1453 participants in the Framingham dementia study sample, the mean (SD) age was 75 (7) years; 792 (54.5%) were female. Among the 367 individuals in the replication cohort, the mean (SD) age was 69 (9) years; 217 (59.1%) were female. Of 134 cases of incident all dementia in the Framingham sample, 105 were AD dementia. After adjustment for age and sex, each SD unit increase in the log of plasma total tau level was associated with a 35% increase in AD dementia risk (hazard ratio [HR], 1.35; 95% CI, 1.10-1.67). The addition of plasma total tau to a model including age and sex improved the stratification of participants for risk of AD dementia (net reclassification improvement, 0.382; 95% CI, 0.030-0.716). Higher plasma total tau level was associated with poorer cognition across 7 cognitive tasks (P < .05) and smaller hippocampi (hippocampal volume: β [SE] = 0.002 [0.001]; P = .003) as well as neurofibrillary tangles (β [SE] = 0.95 [0.45]; P = .04) and microinfarcts (odds ratio, 3.04; 95% CI, 1.26-7.37) at autopsy. In the replication cohort, plasma total tau level weakly correlated with cerebrospinal fluid total tau level (Spearman correlation coefficient, 0.16; P = .07), but plasma total tau was at least as strongly associated with incident AD dementia as cerebrospinal fluid total tau (log plasma total tau: HR, 2.33; 95% CI, 1.00-5.48; log cerebrospinal fluid total tau: HR, 2.14; 95% CI, 1.33-3.44) after adjustment for age and sex. Conclusions and Relevance: The findings suggest that plasma total tau levels may improve the prediction of future dementia, are associated with dementia endophenotypes, and may be used as a biomarker for risk stratification in dementia prevention trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamaneurol.2018.4666

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Research works printed but not linked: 21

  1. Rissin, 2011, Simultaneous detection of single molecules and singulated ensembles of molecules enables immunoassays with broad dynamic range., Anal Chem, 83, 2279, 10.1021/ac103161b · DOI · Paper page
  2. Zetterberg, 2013, Plasma tau levels in Alzheimer’s disease., Alzheimers Res Ther, 5, 9, 10.1186/alzrt163 · DOI · Paper page
  3. Olsson, 2016, CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis., Lancet Neurol, 15, 673, 10.1016/S1474-4422(16)00070-3 · DOI · Paper page
  4. Dage, 2016, Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population-based elderly cohort., Alzheimers Dement, 12, 1226, 10.1016/j.jalz.2016.06.001 · DOI · Paper page
  5. Mielke, 2017, Association of plasma total tau level with cognitive decline and risk of mild cognitive impairment or dementia in the Mayo Clinic study on aging., JAMA Neurol, 74, 1073, 10.1001/jamaneurol.2017.1359 · DOI · Paper page
  6. Feinleib, 1975, The Framingham Offspring Study. design and preliminary data., Prev Med, 4, 518, 10.1016/0091-7435(75)90037-7 · DOI · Paper page
  7. Splansky, 2007, The Third Generation Cohort of the National Heart, Lung, and Blood Institute’s Framingham Heart Study: design, recruitment, and initial examination., Am J Epidemiol, 165, 1328, 10.1093/aje/kwm021 · DOI · Paper page
  8. McKhann, 1984, Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease., Neurology, 34, 939, 10.1212/WNL.34.7.939 · DOI · Paper page
  9. Ahl, 2013, Defining MCI in the Framingham Heart Study Offspring: education versus WRAT-based norms., Alzheimer Dis Assoc Disord, 27, 330, 10.1097/WAD.0b013e31827bde32 · DOI
  10. Aljabar, 2009, Multi-atlas based segmentation of brain images: atlas selection and its effect on accuracy., Neuroimage, 46, 726, 10.1016/j.neuroimage.2009.02.018 · DOI · Paper page
  11. Delacourte, 1999, The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer’s disease., Neurology, 52, 1158, 10.1212/WNL.52.6.1158 · DOI · Paper page
  12. Pencina, 2011, Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers., Stat Med, 30, 11, 10.1002/sim.v30.1 · doi:10.1002/sim.v30.1
  13. Hosmer, 1995, Confidence interval estimates of an index of quality performance based on logistic regression models., Stat Med, 14, 2161, 10.1002/(ISSN)1097-0258 · DOI
  14. Pase, 2017, Role of improved vascular health in the declining incidence of dementia., Stroke, 48, 2013, 10.1161/STROKEAHA.117.013369 · DOI
  15. Dufouil, 2017, Cognitive and imaging markers in non-demented subjects attending a memory clinic: study design and baseline findings of the MEMENTO cohort., Alzheimers Res Ther, 9, 67, 10.1186/s13195-017-0288-0 · DOI
  16. Schraen-Maschke, 2008, Tau as a biomarker of neurodegenerative diseases., Biomark Med, 2, 363, 10.2217/17520363.2.4.363 · DOI
  17. Deters, 2017, Plasma tau association with brain atrophy in mild cognitive impairment and Alzheimer’s disease., J Alzheimers Dis, 58, 1245, 10.3233/JAD-161114 · DOI
  18. Müller, 2017, Tau plasma levels in subjective cognitive decline: results from the DELCODE study., Sci Rep, 7, 9529, 10.1038/s41598-017-08779-0 · DOI
  19. Sperling, 2014, The A4 study: stopping AD before symptoms begin?, Sci Transl Med, 6, 228fs13, 10.1126/scitranslmed.3007941 · DOI · Paper page
  20. American Psychatric Association, 2000, Diagnostic and Statistical Manual of Mental Disorders
  21. Strauss, 2006, A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary

Cited by

See all 204

Metadata

Authors
Pase, M. P., Beiser, A. S., Himali, J. J., Satizabal, C. L., Aparicio, H. J., DeCarli, C., Chêne, G., Dufouil, C., & Seshadri, S.
Venue
JAMA Neurology
Published
2019-05-01
Volume
76
Issue
5
Pages
598
ISSN
2168-6149 (ISSN-L)
OpenAlex
W2920387298
Cited by
204
References
13
FWCI
21.09
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Assessment of Plasma Total Tau Level as a Predictive Biomarker for Dementia and Related Endophenotypes. https://app.cochat.ai/papers/10.1001/jamaneurol.2018.4666
The paper
Pase, M. P., Beiser, A. S., Himali, J. J., Satizabal, C. L., Aparicio, H. J., DeCarli, C., Chêne, G., Dufouil, C., & Seshadri, S. (2019). Assessment of Plasma Total Tau Level as a Predictive Biomarker for Dementia and Related Endophenotypes. JAMA Neurology. https://doi.org/10.1001/jamaneurol.2018.4666

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.